Cancer (With or Without Metastasis) clinical trials

Gait Parameters in Breast Cancer Receiving Chemotherapy Patients

Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery

Adding paclitaxel to standard chemotherapy for tough testicular cancer

This trial tests if adding a drug called paclitaxel to the standard chemotherapy combination (BEP) can improve outcomes for people with aggressive testicular cancer. It is for those whose tumor markers did not drop as fast as expected after the first round of chemo.

Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases

Hormone therapy plus AKT inhibitor before prostate surgery

This study tests a combination of hormone therapy drugs (leuprolide and abiraterone) with an experimental AKT inhibitor (capivasertib) before prostate removal surgery. The goal is to see if this treatment reduces the risk of the cancer coming back in men with high-risk prostate cancer with a specific genetic change called PTEN loss.

AMT-116 for advanced non-squamous lung cancer after prior treatments

This study tests a new drug called AMT-116 for advanced lung cancer that has not responded to standard treatments. It compares AMT-116 to the doctor's choice of chemotherapy. If you qualify, you'll get either the new drug or a standard treatment, and the goal is to see which works better.

Blood test to predict response to immunotherapy in lung cancer and melanoma

This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.

T-DXd injected into spinal fluid for HER2 breast cancer with brain spread

This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.

Bicalutamide with BCG for bladder cancer after BCG treatment

This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.

A new drug plus letrozole for advanced HR+ breast cancer

This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.

Give cancer tissue samples to help future cancer research

This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.

Combination drug therapy for advanced colorectal cancer

This trial tests a combination of three drugs (ivarmacitinib, camrelizumab, and fruquintinib) for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help shrink or control the cancer.

Continued access and long-term safety study

This trial is for people who have been on a Daiichi Sankyo study drug and whose study has ended. It lets you keep getting the treatment while the long-term safety is checked, so you don't have to stop a treatment that is working for you.

Exercise therapy for prostate cancer patients on active surveillance

This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.

Raludotatug Deruxtecan for resistant ovarian cancer

This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.

New pill for POU2F3-positive small cell lung cancer

This trial tests a new pill (FHD-286) that targets a specific marker in small cell lung cancer called POU2F3. The drug aims to stop cancer growth in patients whose tumors have this marker and who have already tried standard chemotherapy.

Using a blood test to guide immunotherapy after bladder/kidney cancer surgery

This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.

Valemetostat and darolutamide for advanced prostate cancer

This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.

Tarlatamab for extensive-stage small-cell lung cancer with poor performance status

This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.

Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy

This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.

Durvalumab plus chemo before surgery for upper tract cancer

This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.

New drug combination for advanced egfr lung cancer

This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.

MUC1 peptide vaccine study for non-small cell lung cancer

This trial tests a vaccine made from a lung-cancer target (MUC1) to help your immune system recognize and fight the cancer. It is designed to measure immune response and safety, and it may help some people develop a stronger anti-cancer immune reaction.

Smoking cessation support for people with cancer

This trial tests a program to help people with cancer quit smoking cigarettes. It may help you quit and improve your overall health during cancer treatment.